InstalabLoading...
InstalabLoading...
Your immune system is built to attack invaders and leave your own cells alone. But sometimes that targeting system breaks down, and your body starts producing antibodies that latch onto the insides of your own cells, specifically the proteins and DNA inside the nucleus. An ANA (antinuclear antibody) screen detects whether those self-targeting antibodies are circulating in your blood.
This test matters because autoimmune diseases like lupus, Sjogren's syndrome, and scleroderma can simmer for years before obvious symptoms appear. Catching immune misdirection early gives you the chance to investigate further, track your trend, and act before organ damage begins.
The ANA screen looks for a broad family of antibodies that target components inside the cell nucleus, including DNA, proteins called histones, and particles involved in reading genetic instructions (ribonucleoproteins). These antibodies are produced by immune cells called B lymphocytes, which normally learn to ignore your own tissues. When that training fails, these cells start churning out antinuclear antibodies that can damage tissues throughout the body.
The test result is reported as either positive or negative. If positive, it is typically followed by a titer (a measure of concentration, expressed as a ratio like 1:80 or 1:320) and a fluorescence pattern (a visual signature that reveals which specific nuclear targets the antibodies are attacking). Both matter for interpretation: the titer tells you how much antibody is present, while the pattern points toward which disease, if any, might be involved. A positive ANA with one pattern can suggest lupus, while the same titer with a different pattern can suggest an entirely different condition or no disease at all.
The strongest association is with systemic lupus erythematosus (SLE), a condition in which the immune system attacks joints, skin, kidneys, and other organs. Nearly all lupus patients test ANA-positive, which is why international classification guidelines now require a positive ANA at a titer of 1:80 or higher as the first step before a lupus diagnosis can even be considered.
In a general population study of about 2,800 people followed for 15 years, those with ANA titers at or above 1:160 were roughly 14 times more likely to develop a connective tissue disease than those who tested negative (HR 14.19). That is a striking increase in risk, though the absolute number who developed disease was still small, reflecting how uncommon these conditions are in the general population.
A Dutch study of about 1,000 patients with suspected connective tissue disease found that a negative ANA was extremely good at ruling out these conditions, with a negative predictive value of 98%. The positive predictive value, however, was only 7%, meaning most people with a positive ANA did not have connective tissue disease. This asymmetry is the central tension of the test: it catches nearly everyone who has the disease, but it also flags many people who are perfectly healthy.
A positive ANA also shows up in Sjogren's syndrome (which attacks moisture-producing glands), systemic sclerosis (which causes skin and organ scarring), inflammatory muscle diseases, rheumatoid arthritis, autoimmune hepatitis, and autoimmune thyroid disease. Each of these conditions tends to produce a different fluorescence pattern, which is why the pattern reported on your lab result is just as important as the titer for narrowing down what a positive ANA might mean. Follow-up antibody testing is then guided by the pattern to confirm or rule out specific conditions.
In the Baltimore Longitudinal Study of Aging, ANA-positive women had about twice the odds of having type 2 diabetes (OR 2.06) and roughly 2.5 times the odds of having two or more chronic diseases (OR 2.47) compared to ANA-negative women. No similar associations were found in men, suggesting that autoimmune signaling may interact with metabolic health differently depending on sex.
If you are wondering whether a positive ANA means a shorter life or higher cancer risk, the current evidence says no. In a U.S. population study of about 3,400 adults followed for roughly 9 years, ANA positivity was not significantly associated with dying from any cause (HR 1.13), heart disease (HR 1.60), or cancer (HR 1.58), with all confidence intervals crossing 1.0. A separate 15-year Italian cohort of about 2,800 people confirmed the same pattern: no significant link between ANA positivity and cancer or overall mortality.
The one exception worth noting: ANA-positive men who already had a history of cancer showed elevated all-cause mortality (HR 2.28). This suggests the combination of existing cancer plus immune dysregulation may carry added risk, but ANA positivity alone does not appear to shorten your life.
This is where ANA testing gets tricky. Between 7% and 30% of healthy people with no autoimmune disease test positive, depending on which lab method is used and which titer cutoff is applied. U.S. population data shows ANA prevalence rose from 11% in the late 1980s to about 16% by 2012, representing roughly 41 million Americans. Among healthy adults over 65, up to one-third may test positive.
This high rate of positivity in healthy people is the main reason the test is not recommended as a general screening tool. In primary care settings where the chance of autoimmune disease is low, a positive ANA triggers anxiety, follow-up testing, specialist referrals, and costs, with very few actual diagnoses at the end. In one rheumatology clinic study, only about 2% of patients referred for a positive ANA turned out to have lupus, and only about 9% had any ANA-associated autoimmune disease.
Two pieces of information matter most when interpreting a positive ANA: the titer and the fluorescence pattern. The titer tells you how concentrated the antibodies are, with higher titers carrying more diagnostic weight. The fluorescence pattern tells you which nuclear structures the antibodies are targeting, which points toward different diseases. A homogeneous pattern (where the entire nucleus lights up) is the one most associated with lupus, while a speckled pattern is common in Sjogren's syndrome, mixed connective tissue disease, and many healthy people. A centromere pattern points toward limited scleroderma, and a nucleolar pattern toward diffuse scleroderma. The same titer can mean very different things depending on the pattern it comes with.
| ANA Titer | Sensitivity for Lupus | Specificity for Lupus |
|---|---|---|
| 1:80 or higher | About 98% | About 75% |
| 1:160 or higher | About 96% | About 86% |
| 1:320 or higher | About 86% | About 97% |
These numbers apply specifically to lupus and only tell part of the story. A high titer with a speckled pattern, for example, points away from lupus and toward conditions like Sjogren's syndrome or mixed connective tissue disease, even though the titer itself looks alarming. A moderate titer with a homogeneous pattern is more suggestive of lupus than a higher titer with a centromere pattern. Your lab report will include both the titer and the pattern, and both matter for determining what follow-up testing makes sense. The pattern guides which specific antibody tests to order: anti-dsDNA and anti-Smith for a homogeneous pattern, SS-A/SS-B for a speckled pattern, anti-centromere for a centromere pattern, and anti-Scl-70 for a nucleolar pattern.
Several factors can produce a positive ANA that has nothing to do with autoimmune disease. Knowing these will help you avoid drawing the wrong conclusions from a single result.
Acute exercise, fasting, and diet do not appear to affect ANA results in the short term. Unlike inflammatory markers such as CRP, ANA reflects a stable immune memory rather than a quick-reacting stress response, so you do not need to fast or avoid the gym before testing.
ANA testing differs from most biomarkers in that serial retesting is generally not useful. In a large study of nearly 5,000 patients with repeat ANA tests, about 78% had unchanged results over time. Among those who initially tested negative and later converted to positive, the positive predictive value for a new autoimmune diagnosis was only 1.1%. The five patients who did develop a connective tissue disease after converting all had evolving clinical symptoms, meaning their changing clinical picture, not the repeat ANA, was the real signal.
The practical takeaway: if your ANA is negative and your symptoms have not changed, repeating the test is unlikely to reveal anything new. If your ANA is positive, the next move is specific antibody testing and clinical evaluation, not simply rechecking the ANA. The exception is if your clinical picture changes meaningfully, such as developing new joint pain, skin rashes, unexplained fevers, or kidney problems. In that situation, a new round of testing (including ANA and more targeted antibodies) is warranted.
For the technically minded: the intra-assay coefficient of variation (a measure of how much a test result varies when the same sample is tested repeatedly) averages about 11%, and low-titer results show particularly poor repeatability. High-titer results are much more consistent. This means a borderline positive at 1:80 may not reproduce on retesting, while a result of 1:320 or higher is far more stable.
ANA testing delivers the most useful information when you already have symptoms that could point to an autoimmune disease: unexplained joint pain with swelling, skin rashes triggered by sunlight, persistent fatigue combined with fevers, unexplained kidney problems, or mouth ulcers. In these situations, a positive ANA at a meaningful titer helps direct further workup and speeds up diagnosis.
For someone without symptoms, a positive ANA is far more likely to be a false positive than a true early warning. That said, if you have a strong family history of lupus or other autoimmune diseases, or if you belong to a demographic group with higher autoimmune risk (women, particularly of African American, Hispanic, or Asian descent), getting a baseline ANA can give you information to act on if symptoms eventually develop. Having a prior result on file means you can compare rather than starting from scratch.
Evidence-backed interventions that affect your ANA Screen level
ANA Screen is best interpreted alongside these tests.